Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression

European Psychiatry

Volumn 27, Issue 2, 2012, Pages 114-128

  Moller H J ^a   Bitter, I ^b   Bobes, J ^c   Fountoulakis, K ^d   Hoschl C ^e   Kasper, S ^f  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^c UNIVERSIDAD DE OVIEDO   (Spain)

^d ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^e CHARLES UNIVERSITY   (Czech Republic)

^f MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Antidepressants; Depression treatment; Efficacy; Review; Suicidality

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; DULOXETINE; ESCITALOPRAM; MILNACIPRAN; MIRTAZAPINE; NEFAZODONE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ACUTE DISEASE; AGITATION; ANXIETY; ARTICLE; BLOOD LEVEL; CAREGIVER BURDEN; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CONTROLLED CLINICAL TRIAL (TOPIC); DATA BASE; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; HEREDITY; HUMAN; INSOMNIA; LIBIDO; MAJOR DEPRESSION; MEDICAL EDUCATION; MEDICAL SOCIETY; META ANALYSIS (TOPIC); MONOTHERAPY; MULTICENTER STUDY (TOPIC); NAUSEA; NERVOUSNESS; PATHOGENESIS; PERSONALITY DISORDER; PERSONALIZED MEDICINE; PHARMACOGENETICS; PREDICTOR VARIABLE; PRIORITY JOURNAL; PSYCHIATRIST; PSYCHOTHERAPY; SIDE EFFECT; SUICIDE;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; EVIDENCE-BASED MEDICINE; HUMANS; PSYCHOTHERAPY; SUICIDE;

EID: 84856582927     PISSN: 09249338     EISSN: 17783585     Source Type: Journal    
DOI: 10.1016/j.eurpsy.2011.08.002     Document Type: Article

References (209)

1. Adli M., Bauer M., Rush A.J. Algorithms and collaborative care systems for depression: are they effective and why?. Biol Psychiatry 2006, 59:1029-1038.
2. Adli M., Berghöfer A., Linden M., Helmchen H., Müller-Oerlinghausen B., Mackert A., et al. Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorders: results of a 2-year observational algorithm study. J Clin Psychiatry 2002, 63(9):782-790.
3. Alonso J., Angermeyer M.C., Bernert S., Bruffaerts R., Brugha T.S., Bryson H., et al. Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl 2004, 420:21-27.
4. American Psychiatric Association. APA Practice Guidelines - treatment of patients with major depressive disorder, Second Edition. [Second]. 2000. [Ref Type: Electronic Citation]. http://www.psychiatryonline.com/pracGuide/pracGuideChapToc_7.aspx.
5. Anderson I.M. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Disord 2000, 58(1):19-36.
6. Anderson I.M., Ferrier I.N., Baldwin R.C., Cowen P.J., Howard L., Lewis G., et al. Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol 2008, 22(4):343-396.
7. Angst J., Angst F., Gerber-Werder R., Gamma A. Suicide in 406 mood-disorder patients with and without long-term medication: a 40 to 44 years' follow-up. Arch Suicide Res 2005, 9(3):279-300.
8. Angst J., Gamma A., Sellaro R., Zhang H., Merikangas K. Toward validation of atypical depression in the community: results of the Zurich cohort study. J Affect Disord 2002, 72(1):125-138.
9. Baghai T.C., Volz H.P., Moller H.J. Drug treatment of depression in the 2000s: an overview of achievements in the last 10 years and future possibilities. World J Biol Psychiatry 2006, 7(4):198-222.
10. Balazs J., Benazzi F., Rihmer Z., Rihmer A., Akiskal K.K., Akiskal H.S. The close link between suicide attempts and mixed (bipolar) depression: implications for suicide prevention. J Affect Disord 2006, 91(2-3):133-138.
11. Baldwin D., Broich K., Fritze J., Kasper S., Westenberg H., Möller H.J. Placebo-controlled studies in depression: necessary, ethical and feasible. Eur Arch Psychiatry Clin Neurosci 2003, 253:22-28.
12. Barbui C., Campomori A., D'Avanzo B., Negri E., Garattini S. Antidepressant drug use in Italy since the introduction of SSRIs: national trends, regional differences and impact on suicide rates. Soc Psychiatry Psychiatr Epidemiol 1999, 34(3):152-156.
13. Bauer M., Bschor T., Pfennig A., Whybrow P.C., Angst J., Versiani M., et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care. World J Biol Psychiatry 2007, 8(2):67-104.
14. Bauer M., Tharmanathan P., Volz H.P., Moeller H.J., Freemantle N. The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis. Eur Arch Psychiatry Clin Neurosci 2009, 259(3):172-185.
15. Bauer M, Whybrow PC, Angst J, Versiani M, Möller HJ, WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, Part 1: acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 2002;3:5-43 [Ref Type: Journal (Full)].
16. Bauer M.S., Wisniewski S.R., Marangell L.B., Chessick C.A., Allen M.H., Dennehy E.B., et al. Are antidepressants associated with new-onset suicidality in bipolar disorder? A prospective study of participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). J Clin Psychiatry 2006, 67(1):48-55.
17. Bech P. Depressive symptomatology and drug response. Commun Psychopharmacol 1978, 2(5):409-418.
18. Bech P. Is the antidepressive effect of second-generation antidepressants a myth?. Psychol Med 2009, 1-6.
19. Belmaker R.H., Agam G. Major depressive disorder. N Engl J Med 2008, 358(1):55-68.
20. Benazzi F., Akiskal H.S. How best identify to a bipolar-related subtype among major depressive patients without spontaneous hypomania: superiority of age at onset criterion over recurrence and polarity?. J Affect Disord 2008, 107(1-3):77-88.
21. Brent D.A. Antidepressants and pediatric depression - the risk of doing nothing. N Engl J Med 2004, 351:1598-1601.
22. Bschor T., Berghöfer A., Ströhle A., Kunz D., Adli M., Müller-Oerlinghausen B., et al. How long should the lithium augmentation strategy be maintained? A 1-year follow-up of a placebo-controlled study in unipolar refractory major depression. J Clin Psychopharmacol 2002, 22(4):427-430.
23. Caspi A., Moffitt T.E. Gene-environment interactions in psychiatry: joining forces with neuroscience. Nat Rev Neurosci 2006, 7(7):583-590.
24. Cipriani A., Furukawa T.A., Salanti G., Geddes J.R., Higgins J.P., Churchill R., et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009, 373(9665):746-758.
25. Crossley N.A., Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry 2007, 68(6):935-940.
26. Cuijpers P., van Straten A., Warmerdam L. Behavioral activation treatments of depression: a meta-analysis. Clin Psychol Rev 2007, 27(3):318-326.
27. de Maat S., Dekker J., Schoevers R., van Aalst G., Gijsbers-van Wijk C., Hendriksen M., et al. Short psychodynamic supportive psychotherapy, antidepressants, and their combination in the treatment of major depression: a mega-analysis based on three randomized clinical trials. Depress Anxiety 2008, 25(7):565-574.
28. Deutsche Gesellschaft für Psychiatrie PuN. S3-Leitlinien/Nationale VersorgungsLeitlinie Unipolare Depression. In: DGPPN, BÄK, KBV, AWMF, AkdÄ B, BApK et al., editors. 2009. Berlin, Düsseldorf, Deutsche Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde.
29. Drago A., De Ronchi D., Serretti A. Pharmacogenetics of antidepressant response: an update. Hum Genomics 2009, 3(3):257-274.
30. European Medicines Agency Press Office. European Medicines Agency finalises review of antidepressants in children and adolescents. 2005 Ref Type: Internet Communication. http://www.ema.europa.eu/pdfs/human/press/pr/12891805en.pdf.
31. Fava G.A., Grandi S., Zielezny M., Canestrari R., Morphy M.A. Cognitive behavioural treatment of residual symptoms in primary major depressive disorder. Am J Psychiatry 1994, 151:1295-1299.
32. Fava G.A., Grandi S., Zielezny M., Rafanelli C., Canestrari R. Four-year outcome for cognitive behavioural treatment of residual symptoms in major depression. Am J Psychiatry 1996, 153:945-947.
33. Fava G.A., Rafanelli C., Grandi S., Canestrari R., Morphy M.A. Six year outcome for cognitive behavioural treatment of residual symptoms in major depression. Am J Psychiatry 1998, 155:1443-1445.
34. Fergusson D., Doucette S., Glass K.C., Shapiro S., Healy D., Hebert P., et al. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. BMJ 2005, 330(7488):396.
35. Fountoulakis KN, Möller HJ. Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int J Neuropsychopharmacol 2011;14(3):405-12.
36. Fournier J.C., DeRubeis R.J., Hollon S.D., Dimidjian S., Amsterdam J.D., Shelton R.C., et al. Antidepressant drug effects and depression severity. A patient-level meta-analysis. JAMA 2010, 303(1):47-53.
37. Frank E., Kupfer D., Perel J., Cornes C., Jarrett D., Mallinger A. Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 1990, 47:1093-1099.
38. Frey R., Schreinzer D., Stimpfl T., Vycudilik W., Berzlanovich A., Kasper S. Suicide by antidepressant intoxication identified at autopsy in Vienna from 1991-1997: the favourable consequences of the increasing use of SSRIs. Eur Neuropsychopharmacol 2000, 10:133-142.
39. Friedman M.A., Detweiler-Bedell J.B., Leventhal H.W., Horne R., Keitner G.I., Miller I.W. Combined psychotherapy and pharmacotherapy for the treatment of depression disorder. Clin Psychol Sci Pract 2004, 11:47-68.
40. Fritze J., Möller H.J. Design of clinical trials of antidepressants. Should a placebo control arm be included?. CNS Drugs 2001, 15(10):755-764. [Ref Type: Journal (Full)].
41. Frodl T., Meisenzahl E.M., Zill P., Baghai T., Rujescu D., Leinsinger G., et al. Reduced hippocampal volumes associated with the long variant of the serotonin transporter polymorphism in major depression. Arch Gen Psychiatry 2004, 61(2):177-183.
42. Frodl T., Moller H.J., Meisenzahl E. Neuroimaging genetics: new perspectives in research on major depression?. Acta Psychiatr Scand 2008, 118(5):363-372.
43. Fulford K.W.M. Facts/values: ten principles of value-based medicine. The philosophy of psychiatry: a companion 2004, Oxford University Press, New York. J. Radden (Ed.).
44. Geddes J.R., Carney S.M., Davies C., Furukawa T.A., Kupfer D.J., Frank E., et al. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet 2003, 361(9358):653-661.
45. Geddes J.R., Cipriani A. Selective serotonin reuptake inhibitors. BMJ 2004, 329(7470):809-810.
46. Gibbons R.D., Brown C.H., Hur K., Marcus S.M., Bhaumik D.K., Erkens J.A., et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adolescents. Am J Psychiatry 2007, 164(9):1356-1363.
47. Goodwin G.M., Emsley R., Rembry S., Rouillon F. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009, 70(8):1128-1137.
48. Grunebaum M.F., Ellis S.P., Li S., Oquendo M.A., Mann J.J. Antidepressants and sucide risk in the United States, 1985-1999. J Clin Psychiatry 2004, 65(1):1456-1462.
49. Grunze H., Vieta E., Goodwin G.M., Bowden C., Licht R.W., Möller H.J., et al. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 2010, 11(2):81-109.
50. Guaiana G., Andretta M., Corbari L., Mirandola M., Sorio A., D'Avanzo B., et al. Antidepressant drug consumption and public health indicators in Italy, 1955 to 2000. J Clin Psychiatry 2005, 66(6):750-755.
51. Gunnell D., Saperia J., Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ 2005, 330:385-389.
52. Hammad T. Review and evaluation of clinical data: relationship between psychotropic drugs and pediatric suicidality.. 16-8-2004. Ref Type: Electronic Citation. http://www.fda.gov/OHRMS/DOCKETS/AC/04/briefing/2004-4065b1-10-TAB08-Hammads-Review.pdf.
53. Hammad T.A., Laughren T., Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006, 63(3):332-339.
54. Hegerl U., Gallinat J., Juckel G. Event-related potentials. Do they reflect central serotonergic neurotransmission and do they predict clinical response to serotonin agonists?. J Affect Disord 2001, 62(1-2):93-100.
55. Hegerl U., Hautzinger M., Mergl R., Kohnen R., Schütze M., Scheunemann W., et al. Effects of pharmacotherapy and psychotherapy in depressed primary care patients: a randomised, controlled trial including a patient choice arm. Int J Neuropsychopharmacol 2010, 13(1):31-44.
56. Hegerl U., Mergl R. The clinical significance of antidepressant treatment effects cannot be derived from placebo-verum response differences. J Psychopharmacol 2010, 24(4):445-448.
57. Hegerl U., Mergl R., Havers I., Schmidtke A., Lehfeld H., Niklewski G., et al. Sustainable effects on suicidality were found for the Nuremberg alliance against depression. Eur Arch Psychiatry Clin Neurosci 2010, (5):401-406.
58. Hegerl U., Plattner A., Moller H.J. Should combined pharmaco- and psychotherapy be offered to depressed patients? A qualitative review of randomized clinical trials from the 1990s. Eur Arch Psychiatry Clin Neurosci 2004, 254(2):99-107.
59. Hegerl U., Seemann O., Müller-Siecheneder F. Depression and suicidal behavior more effectively controlled by a team approach. Pilot project to optimize diagnosis and therapy. MMW Fortschr Med 1999, 141(48):43-45. [Article in German].
60. Henkel V., Mergl R., Allgaier A.K., Kohnen R., Möller H.J., Hegerl U. Treatment of depression with atypical features: a meta-analytic approach. Psychiatry Res 2006, 141(1):89-101.
61. Henkel V., Mergl R., Kohnen R., Maier W., Möller H.J., Hegerl U. Identifying depression in primary care: a comparison of different methods in a prospective cohort study. BMJ 2003, 326(7382):200-201.
62. Henkel V, Seemüller F, Obermeier M, Adli M, Bauer M, Kronmüller K et al. Relationship between baseline severity of depression and antidepressant treatment outcome. Pharmacopsychiatry 2011;44(1):27-32.
63. Henkel V., Seemuller F., Obermeier M., Adli M., Bauer M., Mundt C., et al. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. J Affect Disord 2009, 115(3):439-449.
64. Hirschfeld R.M., Montgomery S.A., Aguglia E., Amore M., Delgado P.L., Gastpar M., et al. Partial response and nonresponse to antidepressant therapy: current approaches and treatment options. J Clin Psychiatry 2002, 63(9):826-837.
65. Holsboer F., Ising M. Central CRH system in depression and anxiety - evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol 2008, 583:350-357.
66. Horder J, Matthews P, Waldmann R. Placebo, Prozac and PLoS: significant lessons for psychopharmacology. J Psychopharmacol 2010, [Epub ahead of print].
67. Höschl C., Svestka J. Escitalopram for the treatment of major depression and anxiety disorders. Expert Rev Neurother 2008, 8(4):537-552.
68. Huf W, Kalcher K, Pail G, Friedrich ME, Filzmoser P, Kasper S. Meta-Analysis: fact or fiction? How to interpret meta-analyses. World J Biol Psychiatry 2011;12(3):188-200.
69. Isacsson G. Suicide prevention - a medical breakthrough?. Acta Psychiatr Scand 2000, 102:113-117.
70. Kahn A., Khan S. Placebo response in depression: a perspective for clinical practice. Psychopharmacol Bull 2008, 41(3):91-98.
71. Kahn R.S., Fleischhacker W.W., Boter H., Davidson M., Vergouwe Y., Keet I.P., et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008, 371(9618):1085-1097.
72. Karasu T.B., Gelenberg A., Merriam A., Wang P. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000, 157:1-45. American Psychiatric Association.
73. Kasper S., Hamon M. Agomelatine, a new antidepressant with an innovative mechanism of action - an overview on its preclinical and clinical development program. World J Biol Psychiatry 2009, 10:117-126.
74. Kasper S., Montgomery S.A., Möller H.J., van Oers H.J.J., Schutte A.J., Vrijland P., et al. Longitudinal analysis of the suicidal behavior risk in placebo-controlled studies of mirtazapine in major depressive disorder. World J Biol Psychiatry 2010, 11:36-44.
75. Kasper S., Sacher J., Klein N., Mossaheb N., Attarbaschi-Steiner T., Lanzenberger R., et al. Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram. Int Clin Psychopharmacol 2009, 24(3):119-125.
76. Kato T. Molecular genetics of bipolar disorder and depression. Psychiatry Clin Neurosci 2007, 61(1):3-19.
77. Katon W., Robinson P., von Korff M., Lin E., Bush T., Ludman E., et al. A mutlifaceted intervention to improve treatment of depression in primary care. Arch Gen Psychiatry 1996, 53(10):924-932.
78. Keller M.B. Rationale and options for the long-term treatment of depression. Hum Psychopharmacol 2002, 17Suppl1:S43-S46.
79. Keller M.B., Gelenberg A.J., Hirschfeld R.M., Rush A.J., Thase M.E., Kocsis J.H., et al. The treatment of chronic depression, part 2: a double-blind, randomized trial of sertraline and imipramine. J Clin Psychiatry 1998, 59(11):598-607.
80. Keller M.B., McCullough J.P., Klein D.N., Arnow B., Dunner D.L., Gelenberg A.J., et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000, 342(20):1462-1470.
81. Keller M.B., Trivedi M.H., Thase M.E., Shelton R.C., Kornstein S.G., Nemeroff C.B., et al. The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry 2007, 68(8):1246-1256.
82. Kelsey J.E., Entsuah R. Abstract P. 4. W. 031. Neuropsychopharmacol 2002, 5(Suppl. 1):S207. [Ref Type: Abstract].
83. Kessing L.V. Severity of depressive episodes according to ICD-10: prediction of risk of relapse and suicide. Br J Psychiatry 2004, 184:153-156.
84. Khan A., Detke M., Khan S.R., Mallinckrodt C. Placebo response and antidepressant clinical trial outcome. J Psychiatr Res 2003, 191(4):211-218.
85. Khan A., Khan S. Placebo response in depression: a perspective for clinical practice. Psychopharmacol Bull 2008, 41(3):91-98.
86. Khan A., Leventhal R.M., Khan S.R., Brown W.A. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol 2002, 22(1):40-45.
87. Kirsch I., Deacon B.J., Huedo-Medina T.B., Scoboria A., Moore T.J., Johnson B.T. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008, 5(2):e45.
88. Kirsch I, Moore TJ, Scoboria A, Nicholls S. The emperor's new drugs: an analyses of antidepressant medication data submitted to the U.S. Food and Drug Administration. Prev Treat 2002;23:5.
89. Klein DF. Listening to meta-analysis but hearing bias. Prev Treat 1, Article 0006c, posted June 26, 1998. 1998. [Ref Type: Electronic Citation]. http://journals.apa.org/prevention/volume1/pre0010006c.html.
90. Kocsis J.H., Leon A.C., Markowitz J.C., Manber R., Arnow B., Klein D.N., et al. Patient preference as a moderator of outcome for chronic forms of major depressive disorder treated with nefazodone, cognitive behavioral analysis system of psychotherapy, or their combination. J Clin Psychiatry 2009, 70(3):354-361.
91. Koran L.M., Gelenberg A.J., Kornstein S.G., Howland R.H., Friedman R.A., DeBattista C., et al. Sertraline versus imipramine to prevent relapse in chronic depression. J Affect Disord 2001, 65(1):27-36.
92. Lam R.W., Hossie H., Solomons K., Yatham L.N. Citalopram and Bupropion-SR: combining versus switching in patients with treatment-resistant depression. J Clin Psychiatry 2004, 65(3):337-340.
93. Laux G., Baumann P., Hiemke C. TDM group of the Arbeitsgemeinschaft Neuropsychopharmakologie und Pharmakopsychiatrie. Therapeutic drug monitoring of antidepressants - clinical aspects. J Neural Transm Suppl 2007, 72:261-267.
94. Lépine J.P., Caillard V., Bisserbe J.C., Troy S., Hotton J.M., Boyer P. A randomized, placebo-controlled trial of sertraline for prophylactic treatment of highly recurrent major depressive disorder. Am J Psychiatry 2004, 161(5):836-842.
95. Lépine J.P., Gastpar M., Mendlewicz J., Tylee A. Depression in the community: the first pan-European study DEPRES (Depression Research in European Society). Int Clin Psychopharmacol 1997, 12(1):19-29.
96. Lepola U., Wade A., Andersen H.F. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol 2004, 19(3):149-155.
97. Lerer B., Macciardi F. Pharmacogenetics of antidepressant and mood-stabilizing drugs: a review of candidate-gene studies and future research directions. Int J Neuropsychopharmacol 2002, 5(3):255-275.
98. Lichtenberg P., Belmaker R.H. Subtyping major depressive disorder. Psychother Psychosom 2010, 79:131-135.
99. Llorca P.M., Azorin J.M., Despiegel N., Verpillat P. Efficacy of escitalopram in patients with severe depression: a pooled analysis. Int J Clin Pract 2005, 59(3):268-275.
100. Lopez A.D., Murray C.J.L. The global burden of disease, 1990-2020. Nat Med 1998, 4(11):1241-1243.
101. Lyness J.M., Heo M., Datto C.J., Ten Have T.R., Katz I.R., Drayer R., et al. Outcomes of minor and subsyndromal depression among elderly patients in primary care settings. Ann Int Med 2006, 144(7):496-504.
102. Maginn S., Boardman A.P., Craig T.K., Haddad M., Heath G., Stott J. The detection of psychological problems by General Practitioners - influence of ethnicity and other demographic variables. Soc Psychiatry Psychiatr Epidemiol 2004, 39(6):464-471.
103. Maier W., Möller H.J. Meta-analyses: a method to maximise the evidence from clinical studies?. Eur Arch Psychiatry Clin Neurosci 2010, 260(1):17-23.
104. Mallinckrodt C.H., Prakash A., Houston J.P., Swindle R., Detke M.J., Fava M. Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram). Neuropsychobiology 2007, 56(2-3):73-85.
105. Melander H., Salmonson T., Abadie E., Zwieten-Boot B. A regulatory Apologia - a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants. Eur Neuropsychopharmacol 2008, 18(9):623-627.
106. Mitchell A.J., Vaze A., Rao S. Clinical diagnosis of depression in primary care: a meta-analysis. Lancet 2009, 374(9690):609-619.
107. Möller H.J. Antidepressants - do they decrease or increase suicidality?. Pharmacopsychiatry 1992, 25:249-253.
108. Möller H.J. Attempted suicide: efficacy of different aftercare strategies. Int Clin Psychopharmacol 1992, 6Suppl6:58-69.
109. Möller H.J., Suicide suicidality and suicide prevention in affective disorders. Acta Psychiatrica Scandinavica Supplementum 2003, (418):73-80.
110. Möller H.J. Evidence for beneficial effects of antidepressants on suicidality in depressive patients: A systematic review. Eur Arch Psychiatry Clin Neurosci 2006, 256(6):329-343. [Ref Type: Journal (Full)].
111. Möller H.J. Is there evidence for negative effects of antidepressants on suicidality in depressive patients? A systematic review. Eur Arch Psychiatry Clin Neurosci 2006, 256(8):476-496.
112. Möller H.J. Is the identification of the core symptoms of depression clinically relevant?. Medicographia 2008, 30(1):3-8.
113. Möller H.J. Is there a need for a new psychiatric classification at the current state of knowledge?. World J Biol Psychiatry 2008, 9(2):82-85.
114. Möller H.J. Isn't the efficacy of antidepressants clinically relevant?. A critical comment on the results of the metaanalysis by Kirsch et al. Eur Arch Psychiatry Clin Neurosci 2008, 258(8):451-455.
115. Möller H.J Outcomes in major depressive disorder: the evolving concept of remission and its implications for treatment. World J Biol Psychiatry 2008, 9(2):102-114.
116. Möller H.J. Antidepressants: controversies about their efficacy in depression, their effect on suicidality and their place in a complex psychiatric treatment approach. World J Biol Psychiatry 2009, 10(3):180-195.
117. Möller H.J. Is evidence sufficient for evidence-based medicine?. Eur Arch Psychiatry Clin Neurosci 2009, 259(Suppl. 2):S167-S172.
118. Möller H.J. Pharmacological and biological treatment of suicidal individuals. Oxford Textbook of Suicidology and Suicide Prevention. A Global Perspective 2009, 395-405. Oxford University, New York, [Press]. D. Wasserman, C. Wasserman (Eds.).
119. Möller H.J. Standardised rating scales in psychiatry: methodological basis, their possibilities and limitations and descriptions of important rating scales. World J Biol Psychiatry 2009, 10(1):6-26.
120. Möller H.J., Baldwin D.S., Goodwin G., Kasper S., Okasha A., Stein D.J., et al. Do SSRIs or antidepressants in general increase suicidality? WPA Section on Pharmacopsychiatry: consensus statement. Eur Arch Psychiatry Clin Neurosci 2008, 258(Suppl. 3):3-23.
121. Möller H.J., Broich K. Principle standards and problems regarding proof of efficacy in clinical psychopharmacology. Eur Arch Psychiatry Clin Neurosci 2010, 260(1):3-16.
122. Möller H.J., Fischer G., von Zerssen D. Prediction of therapeutic response in acute treatment with antidepressants. Results of an empirical study involving 159 endogenous depressive inpatients. Eur Arch Psychiatry Neurol Sci 1987, 236:349-357.
123. Möller HJ, Henkel V. What are the most effective diagnostic and therapeutic strategies for the management of depression in specialist care? World Health Organisation 2005 [Ref Type: Electronic Citation]. http://www.who.dk/Document/E86602.pdf.
124. Möller H.J., Maier W. Evidence-based medicine in psychopharmacotherpy: possibilities, problems and limitations. Eur Arch Psychiatry Clin Neurosci 2010, 260(1):25-39.
125. Möller H.J., Rujescu D. Pharmacogenetics - genomics and personalized psychiatry. Eur Psychiatry 2010, 25:291-293.
126. Moncrieff J., Kirsch I. Efficacy of antidepressants in adults. BMJ 2005, 331(7509):155-157.
127. Moncrieff J, Wessely S, Hardy R. Active placebos versus antidepressants for depression. Cochrane Database Syst Rev CD003012 2004;(1).
128. Montano C.B. Recognition and treatment of depression in a primary care setting. J Clin Psychiatry 1994, 55 (Suppl):18-37.
129. Montgomery S.A., Andersen H.F. Escitalopram versus venlafaxine XR in the treatment of depression. Int Clin Psychopharmacol 2006, 21(5):297-309.
130. Montgomery S.A., Baldwin D.S., Blier P., Fineberg N.A., Kasper S., Lader M., et al. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol 2007, 22(6):323-329.
131. Montgomery S.A., Kasper S. Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 2007, 22(5):283-291.
132. Montgomery S.A., Möller H.J. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?. Int Clin Psychopharmacol 2009, 24(3):111-118.
133. National Collaborating Centre for Mental Health Depression in adults (update); depression: the treatment and management of depression in adults 2009, National Institute for Health and Clinical Excellence, London.
134. National Institute for Clinical Excellence (NICE) Depression: management of depression in primary and secondary care. Clinical practice guideline No 23 2004, National Institute for Clinical Excellence, London.
135. Nelson J.C., Papakostas G.I. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009, 166(9):980-991.
136. Papakostas G.I. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry 2009, 70(Suppl. 6):16-25.
137. Papakostas G.I., Charles D., Fava M. Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder. World J Biol Psychiatry 2010, 11(2):300-307.
138. Papakostas G.I., Shelton R.C., Smith J., Fava M. Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry 2007, 68:826-831.
139. Papakostas G.I., Thase M.E., Fava M., Nelson J.C., Shelton R.C. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry 2007, 62(11):1217-1227.
140. Parker G. Classifying depression: should paradigms lost be regained?. Am J Psychiatry 2000, 157(8):1195-1203.
141. Parker G. Differential effectiveness of newer and older antidepressants appears mediated by an age effect on the phenotypic expression of depression. Acta Psychiatr Scand 2002, 106(3):168-170.
142. Paykel E.S. Cognitive therapy in relapse prevention in depression. Int J Neuropsychopharmacol 2007, 10(1):131-136.
143. Paykel E.S., Freeling P., Hollyman J.A. Are tricyclic depressants useful for mild depression? A placebo-controlled trial. Pharmacopsychiatry 1988, 21(1):15-18.
144. Paykel E.S., Scott J., Cornwall P.L., Abbott R., Crane C., Pope M., et al. Duration of relapse prevention after cognitive therapy in residual depression: a follow-up of controlled trial. Psychol Med 2005, 35:59-68.
145. Paykel E.S., Scott J., Teasdale J.D., Johnson A.L., Garland A., Moore R., et al. Prevention of relapse in residual depression by cognitive therapy: a controlled trial. Arch Gen Psychiatry 1999, 56(9):829-835.
146. Perlis R.H., Purcell S., Fava M., Fagerness J., Rush A.J., Trivedi M.H., et al. Association between treatment-emergent suicidal ideation with citalopram and polymorphisms near cyclic adenosine monophosphate response element binding protein in the STAR*D study. Arch Gen Psychiatry 2007, 64:689-697.
147. Pigott H.E., Leventhal A.M., Alter G.S., Boren J.J. Efficacy and effectiveness of antidepressants: current status of research. Psychother Psychosom 2010, 79:267-279.
148. Racagni G., Popoli M. Cellular and molecular mechanisms in the long-term action of antidepressants. Dialogues Clin Neurosci 2008, 10(4):385-400.
149. Reynolds C.F., Dew M.A., Pollock B.G., Mulsant B.H., Frank E., Miller M.D., et al. Maintenance treatment of major depression in old age. N Engl J Med 2006, 354(11):1130-1138.
150. Rising K., Bacchetti P., Bero L. Reporting bias in drug trials submitted to the Food and Drug Administration: a review of publication and presentation. PLoS Med 2008, 5(11):e217.
151. Rix S., Paykel E.S., Lelliott P., Tylee A., Freeling P., Gask L., et al. Impact of a national campaign on GP education: an evaluation of the Defeat Depression Campaign. Br J Gen Pract 1999, 49(439):99-102.
152. Rush A.J. STAR*D: what have we learned?. Am J Psychiatry 2007, 164(2):201-204.
153. Rush A.J., Koran L.M., Keller M.B., Markowitz J.C., Harrison W.M., Miceli R.J., et al. The treatment of chronic depression, part 1: study design and rationale for evaluating the comparative efficacy of sertraline and imipramine as acute, crossover, continuation, and maintenance phase therapies. J Clin Psychiatry 1998, 59(11):589-597.
154. Rush A.J., Trivedi M.H., Wisniewski S.R., Nierenberg A.A., Stewart J.W., Warden D., et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006, 163:1905-1917.
155. Rutz W., Von Knorring L., Walinder J., Wistedt B. Effect of an educational program for general practitioners on Gotland on the pattern of prescription of psychotropic drugs. Acta Psychiatr Scand 1990, 82:399-403.
156. Sanchez C., Bogeso K.P., Ebert B., Reines E.H., Braestrup C. Escitalopram versus citalopram: the surprising role of the R-enantiomer. Psychopharmacology (Berl) 2004, 174(2):163-176.
157. Schaub A., Roth E., Goldmann U. Kognitiv-Psychoedukative Therapie zur Bewältigung von Depressionen: Ein Therapiemanual 2006, Hogrefe, Göttingen.
158. Schechter L.E., Ring R.H., Beyer C.E., Hughes Z.A., Khawaja X., Malberg J.E., et al. Innovative approaches for the development of antidepressant drugs: current and future strategies. NeuroRx 2005, 2(4):590-611.
159. Schlaepfer T.E., George M.S., Mayberg G., Mayberg H. WFSBP Guidelines on Brain Stimulation Treatments in Psychiatry. World J Biol Psychiatry 2010, 11:2-18. on behalf of the WFSBP Task Force on Brain Stimulation.
160. Schosser A., Kasper S. The role of pharmacogenetics in the treatment of depression and anxiety disorders. Int Clin Psychopharmacol 2009, 24:277-288.
161. Schramm E., Schneider D., Zobel I., van Calker D., Dykierek P., Kech S., et al. Efficacy of interpersonal psychotherapy plus pharmacotherapy in chronically depressed inpatients. J Affect Disord 2008, 109(1-2):65-73.
162. Seemüller F, Möller HJ, Obermeier M, Bauer M, Adli M, Mundt C, et al. Prediction of response and remission in inpatients with depressive symptoms. J Affect Disord 2011;133(1-2):137-49.
163. Seemüller F., Riedel M., Obermeier M., Bauer M., Adli M., Mundt C., et al. The controversial link between antidepressants and suicidality risks in adults: data from a naturalistic study on a large sample of in-patients with a major depressive episode. Int J Neuropsychopharmacol 2009, 12(2):181-189.
164. Seemüller F., Riedel M., Wickelmaier F., Adli M., Mundt C., Marneros A., et al. Atypical symptoms in hospitalised patients with major depressive episode: frequency, clinical characteristics, and internal validity. J Affect Disord 2008, 108(3):271-278.
165. Serretti A., Cusin C., Rausch J.L., Bondy B., Smeraldi E. Pooling pharmacogenetic studies on the serotonin transporter: a mega-analysis. Psychiatry Res 2006, 145(1):61-65.
166. Serretti A., Kato M., De Ronchi D., Kinoshita T. Meta-analysis of serotonin transporter gene promotor polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007, 12(3):247-257.
167. Seyringer M.E., Kasper S. Ranking antidepressants. Lancet 2009, 373:1760-1761.
168. Sharan P., Saxena S. Treatment-resistant depression: clinical significance, concept and management. Natl Med J India 1998, 11(2):69-79.
169. Sheehan DV, Lecrubier Y. Mini International Neuropsychiatric Interview (M.I.N.I.). Medical Outcome Systems, Inc. 2005 [Ref Type: Electronic Citation].
170. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorin P., Janavs J., Weiller E., et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998, 59(Suppl. 20):22-57.
171. Simon G.E., Savarino J. Suicide attempts among patients starting depression treatment with medications or psychotherapy. Am J Psychiatry 2007, 164(7):1029-1034.
172. Singh I., Rose N. Biomarkers in psychiatry. Nature 2009, 460:202-207.
173. Sinyor M., Levitt A.J., Cheung A.H., Schaffer A., Kiss A., Dowlati Y., et al. Does inclusion of a placebo arm influence response to active antidepressant treatment in randomized controlled trials? Results from pooled and meta-analyses. J Clin Psychiatry 2010, 71(3):270-279.
174. Spitzer R.L., Endicott J., Robins E. Research Diagnostic Criteria (RDC). Biometrics Research 1975, New York State Psychiatric Institute, New York.
175. Stone M., Jones M.L., Levenson M., Holland P.C., Hughes A., Hammad T.A., et al. Risk of suicidality in clinical trials of antidepressants in adults: analysis of proprietary data submitted to US Food and Drug Administration. BMJ 2009, 339:b2880.
176. Stone MB, Jones ML. Clinical review: Relationship between antidepressant drugs and suicidality in adults. 17-11-2006 [Ref Type: Electronic Citation]. http://www.fda.gov/OHRMS/DOCKETS/AC/06/briefing/2006-4272b1-01-FDA.pdf.
177. Storosum J.G., Elferink A.J., van Zwieten B.J., van den B.W., Gersons B.P., van Strik R., et al. Short-term efficacy of tricyclic antidepressants revisited: a meta-analytic study. Eur Neuropsychopharmacol 2001, 11(2):173-180.
178. Sullivan P.F., Neale M.C., Kendler K.S. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry 2000, 157(10):1552-1562.
179. Swinkels J.A., de Jonghe F. Safety of antidepressants. Int Clin Psychopharmacol 1995, 9(Suppl. 4):19-25.
180. Szegedi A., Jansen W.T., van Willigenburg A.P., van der M.E., Stassen H.H., Thase M.E. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. J Clin Psychiatry 2009, 70(3):344-353.
181. Tadic A., Muller M.J., Rujescu D., Kohnen R., Stassen H.H., Dahmen N., et al. The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. Am J Med Genet B Neuropsychiatr Genet 2007, 144B(3):325-331.
182. Teicher M.H., Glod C.A., Cole J.O. Antidepressant drugs and the emergence of suicidal tendencies. Drug Safety 1993, 8(3):186-212.
183. Thase M.E., Entsuah A.R., Rudolph R.L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001, 178:234-241.
184. Thase M.E., Pritchett Y.L., Ossanna M.J., Swindle R.W., Xu J., Detke M.J. Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. J Clin Psychopharmacol 2007, 27(6):672-676.
185. Thase M.E., Rush A.J., Howland R.H., Kornstein S.G., Kocsis J.H., Gelenberg A.J., et al. Double-blind switch study of imipramine or sertraline treatment of antidepressant-resistant chronic depression. Arch Gen Psychiatry 2002, 59(3):233-239.
186. Tiihonen J., Lönnqvist J., Wahlbeck K., Klaukka T., Tanskanen A., Haukka J. Antidepressants and risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry 2006, 63:1353-1367.
187. Toprac M.G., Dennehy E.B., Carmody T.J., Crismon M.L., Miller A.L., Trivedi M.H., et al. Implementation of the Texas Medication Algorithm Project patient and family education program. J Clin Psychiatry 2006, 67(9):1362-1372.
188. Trindade E., Menon D., Topfer L.A., Coloma C. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ 1998, 159(10):1245-1252.
189. Trivedi M.H., Rush A.J., Crismon M.L., Kashner T.M., Toprac M.G., Carmody T.J., et al. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry 2004, 61(7):669-680.
190. Trivedi M.H., Rush A.J., Wisniewski S.R., Nierenberg A.A., Warden D., Ritz L., et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006, 163(1):28-40.
191. Turner E.H., Matthews A.M., Linardatos E., Tell R.A., Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 2008, 358(3):252-260.
192. U.S. Food and Drug Administration (FDA). Suicidality in children and adolescents being treated with antidepressant medications. 2004 [Ref Type: Internet Communication]. http://www.fda.gov/cder/drug/antidepressants/SSRIPHA200410.htm.
193. U.S. Food and Drug Administration (FDA). Suicidality in children and adolescents being treated with antidepressant medications. 2007 [Ref Type: Internet Communication]. http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm096273.htm.
194. Uhr M., Tontsch A., Namendorf C., Ripke S., Lucae S., Ising M., et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron 2008, 57(2):203-209.
195. Ustün T.B., Sartorius N. Mental illness - General Health Care: an international study 1995, Wiley, Chichester.
196. Vaiva G., Vaiva G., Ducrocq F., Meyer P., Mathieu D., Philippe A., et al. Effect of telephone contact on further suicide attempts in patients discharged from an emergency department: randomised controlled study. BMJ 2006, 332(7552):1241-1245.
197. Valenstein M., McCarthy J.F., Austin K.L., Greden J.F., Young E.A., Blow F.C. What happened to lithium? Antidepressant augmentation in clinical settings. Am J Psychiatry 2006, 163(7):1219-1225.
198. Volz H.P., Baghai T.C., Möller H.J. Drug treatment of depression in the 2000s - an overview of achievements in the last ten years and future possibilities. World J Biol Psychiatry 2006, 7(4):198-222.
199. Wade A., Andersen H.F. The onset of effect for escitalopram and its relevance for the clinical management of depression. Curr Med Res Opin 2006, 22(11):2101-2110.
200. Wade A.G., Schlaepfer T.E., Andersen H.F., Kilts C.D. Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD). J Psychiatr Res 2009, 43:568-575.
201. Wade A.G., Toumi I., Hemels M.E.H. A probabilistic cost-effectiveness analysis of escitalopram, generic citalopram and venlafaxine as a first-line treatment of major depressive disorder in the UK. Curr Med Res Opin 2005, 21(4):631-641.
202. Weinberger M.I., Sirey J.A., Bruce M.L., Heo M., Papademetriou E., Meyers B.S. Predictors of major depression six months after admission for outpatient treatment. Psychiatr Serv 2008, 59(10):1211-1215.
203. Williams WJr, Barrett J., Oxman T., Frank E., Katon W., Sullivan M., et al. Treatment of dysthymia and minor depression in primary care: a randomized controlled trial in older adults. JAMA 2000, 284:1519-1526.
204. Wittchen H.U., Höfler M., Meister W. Prevalence and recognition of depressive syndromes in German primary care settings: poorly recognized and treated?. Int Clin Psychopharmacol 2001, 16(3):121-135.
205. Wittchen H.U., Holsboer F., Jacobi F. Met and unmet needs in the management of depressive disorder in the community and primary care: the size and breadth of the problem. J Clin Psychiatry 2001, 62(Suppl. 26):23-28.
206. Wittchen H.U., Jacobi F. Size and burden of mental disorders in Europe - a critical review and appraisal of 27 studies. Eur Neuropsychopharmacol 2005, 15:357-376.
207. Wittchen H.U., Knäuper B., Kessler R.C. Lifetime risk of depression. Br J Psychiatry 1994, Suppl. 26:16-22.
208. World Health Organization. The global burden of disease: 2004 update. World Health Organisation. 2008. 5-12-2010 [Ref Type: Electronic Citation].
209. Zobel A.W., Nickel T., Kunzel H.E., Ackl N., Sonntag A., Ising M., et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 2000, 34(3):171-181.